ArticleBMC women's health2026
PAX1/JAM3 methylation in cervical exfoliated cells: a robust diagnostic biomarker for cervical high-grade lesions associated with vaginal dysbiosis.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The cervicovaginal microbiome: an emerging determinant of HPV infection and disease.Journal of virology · 2026Review
- A novel methylation marker on theFrontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis prospective single-center study aimed to investigate the clinical correlation between PAX1/JAM3 methylation (CISCER) assay and clinically evaluated vaginal microecological features in women referred for colposcopy, and to assess the potential complementary diagnostic value for detecting high-grade cervical lesions.
methodsParticipants were recruited from the Gynecologic Colposcopy Outpatient Clinic of Beijing Anzhen Hospital, Capital Medical University, from February 2024 to December 2024. The clinical performance of the CISCER assay and the vaginal microecology composition of the colposcopy-referred subjects were analyzed.
resultsThe methylation levels of PAX1 and JAM3 were elevated in participants with cervical intraepithelial neoplasia 2 (CIN2). When ΔCtPAX1 ≤ 6.6 or ΔCtJAM3 ≤ 10.0, the methylation levels for PAX1 or JAM3 were high (with low ΔCt) in ≧ CIN2 compared to ≤ CIN1 (ΔCtPAX1: 4.25 vs. 9.35; ΔCtJAM3: 9.34 vs. 13.2) groups, reflecting higher methylation in high-grade lesions. For the detection of CIN2 + and CIN3 + lesions, the CISCER assay showed high discriminative accuracy, with AUC values of 0.826 and 0.852, respectively. Notably, the CISCER assay demonstrated superior specificity compared to hrHPV testing (89.1% vs. 7.3% for CIN2-), addressing a major limitation of current screening. Elevated PAX1/JAM3 methylation levels are associated with vaginal dysbiosis—characterized by Lactobacillus depletion and Gardnerella enrichment—and are potential strong predictors of CIN2+.
conclusionsThe PAX1/JAM3 methylation (CISCER) assay for cervical exfoliated cells has robust diagnostic association with high-grade cervical lesions (CIN2+) and correlates with vaginal dysbiosis biomarkers, including Gardnerella enrichment and Lactobacillus depletion, supporting its potential as a molecular triage tool for stratifying hrHPV-positive women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.